Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension

Chest

Volumn 125, Issue 2, 2004, Pages 580-586

  Leuchte, Hanno H ^a   Schwaiblmair, Martin ^a   Baumgartner, Rainer A ^a   Neurohr, Claus F ^a   Kolbe, Tilman ^a   Behr, Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Hypertension; Iloprost; Medical subject heading; Nitric oxide; Pulmonary; Sildenafil

Indexed keywords

ILOPROST; NITRIC OXIDE; PIPERAZINE DERIVATIVE; SILDENAFIL; VASODILATOR AGENT;

ADULT; ARTERIAL OXYGEN TENSION; ARTERIAL PRESSURE; ARTERY RESISTANCE; ARTICLE; CARDIOVASCULAR PERFORMANCE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART OUTPUT; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; OXYGEN SATURATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK ASSESSMENT; TISSUE OXYGENATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 1242329145     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.2.580     Document Type: Article

References (41)

1. D'Alonzo GE, Bart RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective study. Ann Intern Med 1991; 115:343-349
2. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995; 75:51A-54A
3. Wagenvoort C, Wagenvoort N. Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42:1163-1184
4. Fuster V, Steele P, Edwards W, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-587
5. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714-721
6. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719-725
7. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registration Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140:1623-1630
8. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:117-119
9. Sitbon O, Humbert M, Jagot LJ, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265-270
10. Ricciardi MJ, Knight BP, Martinez FJ, et al. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32:1068-1073
11. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
12. Hoeper M, Schwarze M, Ehlerding S, et al. Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
13. Olschewski H, Ghofrani, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension (an uncontrolled trial). Ann Intern Med 2000; 132:435-443
14. Wensel R, Opitz Ch, Ewert, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension; Circulation 2000; 101: 2388-2392
15. Hoeper M, Olschewski H, Ghofrani A, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35:176-181
16. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-824
17. Higgenbottam T, Wheeldon D, Wells F, et al. Long-term treatment with continuous intravenous epoprostenol (prostacyclin) in primary pulmonary hypertension. Lancet 1984; 1:1046-1047
18. Mc Laughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension; N Engl J Med 1998; 338:273-277
19. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuos intravenous epoprostenol with conventional therapy for primary pulmonary hypertension; N Engl J Med 1996; 334:296-301
20. Rubin LJ, Mendoza M, Hood M, et al. Treatment of primary pulmonary hypertension with continuos intravenous prostacyclin (epoprostenol): results of randomised trial. Ann Intern Med 1990; 112:485-491
21. Kleinsasser A, Loeckinger A, Hoermann C, et al. Sildenafil modulates hemodynamic and pulmonary gas exchange. Am J Respir Crit Care Med 2001; 163:339-343
22. Abrams D, Schulze-Neick I, Magee AG. Sildenafil: a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:E4
23. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342
24. Atz AM, Wessel DL. Sildenafil ameliorates effects of nitric oxide withdrawal. Anesthesiology 1999; 91:307-010
25. Bigatello LM, Hess D, Dennehy KC, et al. Sildenafil can increase the response to nitric oxide. Anesthesiology 2000; 92:1827-1829
26. Wilkens HW, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104:1218-1222
27. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522
28. Rich S, ed. Primary pulmonary hypertension: executive summary from the world symposium - primary pulmonary hypertension Evian 1998. Available at: http://www.aafp.org/afp/ 20010501/1789.html. Accessed January 20, 2004
29. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93:484-488
30. Pepke-Zaba J, Higgenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338:1173-1174
31. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care 1995; 151:384-389
32. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900
33. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266:L536-L543
34. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75:725-748
35. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in treatment of erectile dysfunction. N Engl J Med 1998; 338:1397-1404
36. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C
37. Ignarro LJ. Biological actions and properties of the endothelium derived nitric oxide formed and released for artery and vein. Circ Res 1989; 65:1-21
38. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30:535-560
39. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41:485-490
40. Ichinose F, Adrie C, Hurford WE, et al. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 1995; 78:1288-1295
41. Schermuly RT, Roehl A, Weissmann N, et al. Combination of non specific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1361-L1368